

## Virulence factors, antimicrobial resistance patterns, and genetic characteristics of hydrogen sulfide-producing *Escherichia coli* isolated from swine

Hyun-Eui Park<sup>1</sup>, Min-Kyoung Shin<sup>1</sup>, Hong-Tae Park<sup>1</sup>, Seung Won Shin<sup>1</sup>, Myunghwan Jung<sup>1</sup>,  
Young Bin Im<sup>1</sup>, Han Sang Yoo<sup>1,2,\*</sup>

<sup>1</sup>Department of Infectious Disease, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea

<sup>2</sup>Institute of Green Bio Science and Technology, Seoul National University, Pyeongchang 232-916, Korea

(Received: January 10, 2015; Revised: August 20, 2015; Accepted: August 27, 2015)

**Abstract :** *Escherichia (E.) coli* is commensal bacteria found in the intestine; however, some pathogenic strains cause diseases in animals and humans. Although *E. coli* does not typically produce hydrogen sulfide (H<sub>2</sub>S), H<sub>2</sub>S-producing strains of *E. coli* have been identified worldwide. The relationship between virulence and H<sub>2</sub>S production has not yet been determined. Therefore, characteristics of H<sub>2</sub>S-producing isolates obtained from swine feces were evaluated including antibiotic resistance patterns, virulence gene expression, and genetic relatedness. Rates of antibiotic resistance of the H<sub>2</sub>S-producing *E. coli* varied according to antibiotic. Only the *EAST1* gene was detected as a virulence gene in five H<sub>2</sub>S-producing *E. coli* strains. Genes conferring H<sub>2</sub>S production were not transmissible although the *sseA* gene encoding 3-mercaptopyruvate sulfurtransferase was detected in all H<sub>2</sub>S-producing *E. coli* strains. Sequences of the *sseA* gene motif CGSVTA around Cys238 were also identical in all H<sub>2</sub>S-producing *E. coli* strains. Diverse genetic relatedness among the isolates was observed by pulsed-field gel electrophoresis analysis. These results suggested that H<sub>2</sub>S-producing *E. coli* strains were not derived from a specific clone and H<sub>2</sub>S production in *E. coli* is not associated with virulence genes.

**Keywords :** *sseA*, antibiotic resistance, *Escherichia coli*, hydrogen sulfide, virulence factor

### Introduction

Hydrogen sulfide (H<sub>2</sub>S) is the colorless gas, but has distinct odor like rotten egg. The gas can be synthesized by reduction of thiosulfate in some enteric bacteria such as *Salmonella* species, *Edwardsiella tarda*, *Citrobacter freundii*, and *Proteus* species. Therefore, production of H<sub>2</sub>S has been used as a distinct characteristics in the identification of the enteric bacteria. *Escherichia (E.) coli* does not produce H<sub>2</sub>S generally even though the bacterium is the commensal in the intestine of animal and human. However, H<sub>2</sub>S producing strains of *E. coli* have been isolated in worldwide from animal and human [4, 7, 16, 17, 24]. Clinical and biochemical properties and antimicrobial susceptibility properties of H<sub>2</sub>S producing variants of *E. coli* were described [6, 16]. H<sub>2</sub>S producing *E. coli* isolates were reported in poultry, healthy pigs and clinical urine samples [4, 16, 24]. The ability to produce H<sub>2</sub>S in several *E. coli* isolates was transmissible and the transmissible plasmid were also characterized [9, 11, 16].

H<sub>2</sub>S can be produced by three enzymes, cystathionine β-synthase, cystathionine, γ-lyase, and 3-mercaptopyruvate sulfurtransferase (3-MST) [14]. Bacterial H<sub>2</sub>S is produced by

3-MST in many Enterobacteriaceae including *E. coli* [22]. Substitution of Ser240 in catalytic motif CGSGVTA with lysine or alanine altered affinity of 3-MST to thiosulfate [3]. H<sub>2</sub>S has been recognized as highly toxic gas to animals and human. But it was discovered that H<sub>2</sub>S have cytoprotective functions in mammals [13, 14, 25]. Although physiological function of H<sub>2</sub>S as a metabolic end product in bacteria was unclear, a universal function of H<sub>2</sub>S against antibiotics was reported [22]. So, H<sub>2</sub>S producing *E. coli* was expected to have more antibiotic resistance than non-producing strain. As described above, characteristics of H<sub>2</sub>S producing *E. coli* were already investigated [4, 7, 16, 17, 24]. But some characteristics including virulence genes and genetic relatedness were not reported in previous researches. Therefore, virulence genes, antibiotic resistance pattern, and genetic relatedness of our isolates were investigated.

### Materials and Methods

#### Isolation and identification of *E. coli*

Fifty six fecal samples from pig with diarrhea were inoculated to MacConkey agar plate (Oxoid, USA). After incuba-

\*Corresponding author

Tel: +82-2-880-1263, Fax: +82-2-874-2738

E-mail: yoohs@snu.ac.kr

**Table 1.** Oligonucleotide sequences of primers used for virulence genes and *sseA* gene amplification in this study

Target gene		Primer sequence (5'→3')	PCR product size (base pair)	Reference
<i>Stx1</i>	F	TTAGACTTCTCGACTGCAAAG	530	[26]
	R	TGTTGTACGAAATCCCCTCTG		
<i>Stx2</i>	F	CTATATCTGCGCCGGGTCTG	327	[26]
	R	AGACGAAGATGGTCAAA		
<i>STa</i>	F	TCCCCTCTTTTAGTCAGTCAACTG	163	[23]
	R	GCACAGGCAGGATTACAACAAAGT		
<i>STb</i>	F	GCAATAAGGTTGAGGTGAT	368	[15]
	R	GCCTGCAGTGAGAAATGGAC		
<i>F4</i>	F	ATCGGTGGTAGTATCACTGC	601	[20]
	R	AACCTGCGACGTCAACAAGA		
<i>F5</i>	F	TGGGACTCCAATGCTTCTG	450	[20]
	R	TATCCACCATTAGACGGAGC		
<i>F6</i>	F	ATGAGAATGAAAAATCCGCA	567	[19]
	R	CGAATAGTCATTACTGCACT		
<i>F18</i>	F	GTGAAAAGACTAGTGTATTTC	510	[10]
	R	CTTGTAAGTAACCGCGTAAGC		
<i>F41</i>	F	GAGGGACTTTCATCTTTAG	431	[20]
	R	AGTCCATTCCATTTATAGGC		
<i>EAE</i>	F	CATTATGGAACGGCAGAGGT	790	[5]
	R	ATCTTCTGCGTACTGCGTTCA		
<i>LT</i>	F	TTACGGCGTFACTATCCTCTCTA	275	[8]
	R	GGTCTCGGTCAGATATGTGATTC		
<i>AIDA-I</i>	F	ACAGTATCATATGGAGCCA	585	[6]
	R	TGTGCGCCAGAACTATTA		
<i>EAST1</i>	F	TCGGATGCCATCAACACAGT	125	[21]
	R	GTCGCGAGTGACGGCTTTGTAG		
<i>PAA</i>	F	ATGAGGAACATAATGGCAGG	360	[2]
	R	TCTGGTCAGGTCGTC AATAC		
<i>sseA</i>	F	GCCTGGACAGGAGGATCGTA	343	In this study
	R	CTCTCCTTCCGGCAGCTCTA		
<i>sseA-seq</i>	F	TGATCACACTTCCCCGCTTC	603	In this study
	R	TTCACGTTTGGCACATCCAG		

F, forward; R, reverse.

tion of the plates for 24 h at 37°C, pink colored colonies were picked up and subcultured to Muller-Hinton agar (Oxoid) supplemented with 0.68% of sodium thiosulfate and 0.08% of ferric ammonium sulfate. H<sub>2</sub>S production of the isolates was confirmed by using TSI agar (Oxoid). The isolates were identified as *E. coli* by using the VITEK-2 System (bioMérieux, France).

#### Analysis of virulence genes and *sseA* gene

Genes encoding virulence factors and enzymes which involved in H<sub>2</sub>S production were investigated by PCR using primers (Table 1). PCR was performed as described previously, with some modifications [19]. DNA templates were prepared by collection of supernatants of bacterial suspension after centrifugation of bacterial suspensions heated at

95°C for 10 min. PCR reaction mixtures were composed of 1 µL of DNA template (10 ng/µL), 4 µL of dNTP (10 mM), 5 µL of 10x PCR buffer, 10 µM of each primer, and 1.25 Unit of *Taq* polymerase (Intron, Korea) and distilled water up to 50 µL. The PCR was carried out by using the following conditions: denatured at 94°C for 3 min, followed by 35 cycles of 94°C for 30 sec, 60°C (virulence genes) and 57°C (*sseA*) for 30 sec, 72°C for 30 sec, and final extension at 72°C for 5 min. The PCR products were visualized by electrophoresis in 1.5% agarose gel with ethidium bromide staining.

**Antibiotic susceptibility test**

Antibiotic susceptibility test was performed by disk diffusion method according to the recommendations by the National Committee for Clinical Laboratory Standards [18]. The antibiotics included in this study were ampicillin (10 µg/disc), amoxicillin/clavulanic acid (30 µg/disc), cefoxitin (30 µg/disc), cephalothin (30 µg/disc), ceftiofur (30 µg/disc), cefepime (30 µg/disc), chloramphenicol (30 µg/disc), florfenicol (30 µg/disc), colistin (10 µg/disc), gentamycin (10 µg/disc), kanamycin (30 µg/disc), streptomycin (10 µg/disc), nalidixic acid (30 µg/disc), ciprofloxacin (5 µg/disc), enrofloxacin (5 µg/disc), sulfamethoxazole/trimethoprim (25 µg/disc), imipenem (10 µg/disc), and tetracycline (30 µg/disc) (all Oxoid).

**Conjugation assay**

Transferability of H<sub>2</sub>S production was carried out by conjugation assay [12]. Sodium azide resistant *E. coli* J53 strain was used as a recipient. Donor and recipient strains were incubated for 12 h and diluted to 1.0 McFarland scale. Donor and recipient suspensions were mixed at 1 : 5 ratio. The mixtures were incubated at 37°C for 20 h. Mixed cultures were plated into Muller Hinton agar (Oxoid) supplemented with 0.68% of sodium thiosulfate, 0.08% of ferric ammonium sulfate, and 200 µg/mL of sodium azide (Sigma, USA) and incubated for 20 h and observed for production of H<sub>2</sub>S through presence of black precipitation on colony.

**Pulsed-field gel electrophoresis (PFGE)**

PFGE was conducted as previously described with some modifications [12]. In brief, all *E. coli* strains were incubated on blood agar plate at 37°C for 16 h and suspended in 3 mL of cell suspension buffer (100 mM Tris : 100 mM EDTA, pH 8.0) for 4.0 McFarland turbidity standard. 200 µL of bacte-

rial suspensions were mixed with 200 µL of 1% Seakem Gold PFGE agarose (Lonza, USA) and poured into the molds. After bacterial plug became solid, lysis reaction was conducted with cell lysis buffer (50 mM Tris : 50 mM EDTA, pH 8.0, 1% Sarcocyl) at 55°C for 2 h. After lysis reaction, plugs were washed twice with distilled water at 55°C for 15 min and washed 4 times with TE buffer (10 mM Tris : 1 mM EDTA, pH 8.0) at 55°C for 15 min. Restriction enzyme reaction was carried out with 50 U of *Xba* I (Takara Bio, Japan) at 37°C for 2 h. Electrophoresis was performed by using the CHEF Mapper system (Bio-Rad Laboratories, USA). Electrophoresis were performed with 0.5x TBE buffer at 14°C for 18 h. Lambda ladder PFGE marker (New England BioLabs, USA) was used as a standard. After electrophoresis, gel images were obtained by Gel Doc system and analyzed using the GelCompar II software (Applied Maths, Belgium).

**Sequencing of *sseA* gene**

Sequencing of *sseA* gene was performed with PCR amplified products using a 3730xl DNA analyzer (Applied Biosystems, USA). The sequences of *sseA* gene were compared to GenBank database using Blast/blastn algorithm (National Center for Biotechnology Information, USA).

**Statistical analysis**

Differences of antibiotic resistance rate between H<sub>2</sub>S-producing and H<sub>2</sub>S-non producing *E. coli* were statistically analyzed using the Chi-square test with EXCEL software (Microsoft, USA). *P* values of <0.05 were considered as statistically significant.

**Results**

**Isolation and identification of *E. coli***

Sixteen H<sub>2</sub>S producing and 32 H<sub>2</sub>S non-producing *E. coli* were isolated from 56 swine fecal samples (Table 2). H<sub>2</sub>S production of the isolates was different depending on the media. The production was detected with all H<sub>2</sub>S producing *E. coli* in Mueller Hinton agar supplemented with sodium thiosulfate and ferric ammonium sulfate. But the production was not observed in some isolates with triple sugar iron (TSI) agar.

**Table 2.** H<sub>2</sub>S production and virulence genes of *E. coli* isolates from swine feces

Strains	Production of H <sub>2</sub> S		Number (%) of isolates which harbored virulence genes									
	MHA-H <sub>2</sub> S	TSI	<i>Stx2</i>	<i>EAST1</i>	<i>F18</i>	<i>STb</i>	<i>AIDA-I</i>	<i>STa</i>	<i>eaeA</i>	<i>LT</i>	<i>F4</i>	<i>PAA</i>
H <sub>2</sub> S producing strain	16 (100)	8 (50)	0 (0)	5 (31.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
H <sub>2</sub> S non-producing strain	0 (0)	0 (0)	3 (9.38)	10 (31.3)	3 (9.38)	6 (18.8)	4 (12.5)	1 (3.1)	1 (3.1)	3 (9.38)	3 (9.38)	3 (9.38)

### Prevalence of gene encoding virulence factors and *sseA*

*EAST1* gene was detected in five H<sub>2</sub>S producing *E. coli* isolates harbored (31.3%) (Table 2). Other virulence genes were not detected in H<sub>2</sub>S producing *E. coli* isolates. But, 16 H<sub>2</sub>S non-producing *E. coli* isolates harbored several virulence genes. The frequency of virulence genes was as below: *EAST1* (31.3%), *STb* (18.8%), *AIDA-I* (12.5%), *F18* (9.38%), *Stx2* (9.38%), *PAA* (9.38%), *LT* (9.38%), *F4* (9.38%), *STa* (3.1%), and *eaeA* (3.1%). *Stx1*, *F5*, *F6*, and *F41* genes were not detected (data not shown). *sseA* gene was detected in both H<sub>2</sub>S producing and non-producing strains. The sequences of *sseA* gene motif CGSVTA around the Cys238 were also identical regardless of H<sub>2</sub>S production. Furthermore, the gene was not transmissible in the conjugation assay.

### Antibiotic resistance rates

Generally, antibiotics resistance rates of H<sub>2</sub>S producing *E. coli* isolates against each antimicrobial agent were various compared to H<sub>2</sub>S non-producing *E. coli* isolates (Table 3). Higher resistance rate of H<sub>2</sub>S producing *E. coli* isolates were observed in ampicillin, gentamycin, chloramphenicol, streptomycin, ciprofloxacin, enrofloxacin, sulfamethoxazole/trimethoprim, and tetracycline. The antibiotic resistance rates against amoxicillin/clavulanic acid, cephalothin, florfenicol, kanamycin, and nalidixic acid were higher in non-producing *E. coli*

**Table 3.** Antibiotic resistance of H<sub>2</sub>S producing and non-producing *E. coli* isolates

Antibiotics	Number (%) of isolates resistant to antibiotics	
	H <sub>2</sub> S producing strain	H <sub>2</sub> S non-producing strain
Ampicillin	15 (93.8)	27 (84.4)
Amoxicillin/Clavulanic acid	8 (50)	20 (62.5)
Cefoxitin	0 (0)	0 (0)
Cephalothin	8 (50)	26 (81.3)*
Ceftiofur	0 (0)	0 (0)
Cefepime	0 (0)	0 (0)
Chloramphenicol	12 (75)	23 (71.9)
Florfenicol	11 (68.8)	23 (71.9)
Colistin	0 (0)	0 (0)
Gentamycin	7 (43.8)	8 (25)
Kanamycin	5 (31.3)	20 (62.5)
Streptomycin	16 (100)	26 (81.3)
Nalidixic acid	5 (31.3)	17 (53.1)
Ciprofloxacin	4 (25)	4 (12.5)
Enrofloxacin	4 (25)	5 (15.6)
Sulfamethoxazole/Trimethoprim	9 (56.3)	13 (40.6)
Imipenem	0 (0)	0 (0)
Tetracycline	13 (87.5)	24 (75)

\*vs. H<sub>2</sub>S producing strain

isolates than H<sub>2</sub>S producing *E. coli* isolates. Only cephalothin showed statistically significant difference between H<sub>2</sub>S producing and non-producing strains ( $p < 0.05$ ). All strains were susceptible to second or third generation of cephalosporins such as cefoxitin, ceftiofur, and cefepime. In addition, none of the strains was resistance to colistin and imipenem.

### Genetic relatedness

Total 48 strains of H<sub>2</sub>S producing and non-producing *E. coli* were analyzed for genetic relatedness by PFGE. Forty-one distinctive PFGE patterns were identified in 45 *E. coli* isolates (Fig. 1) and 3 strains were confirmed non-typable. PFGE pattern was not related with ability of H<sub>2</sub>S production and virulence genes in this analysis. Strains which isolated in same region showed relatively similar PFGE pattern compared to other strains, but it was not observed in all strains.

## Discussion

Although H<sub>2</sub>S was produced by several Enterobacteriaceae, *E. coli* has been recognized as H<sub>2</sub>S non-producing bacteria. However, H<sub>2</sub>S producing *E. coli* isolates were reported and characterized in several previous studies [4, 7, 16, 17, 24]. But still some characteristics were not investigated in the previous studies including genetic relatedness and virulence genes. Therefore, H<sub>2</sub>S producing *E. coli* were isolated and investigated the presence of virulence genes, genetic relatedness, and antibiotic resistance pattern.

*EAST1* gene was detected in five H<sub>2</sub>S producing *E. coli* isolates. But *EAST1* gene was also detected in non-producing *E. coli* isolates. Other virulence genes were not detected in H<sub>2</sub>S producing *E. coli* isolates. This result suggested that H<sub>2</sub>S production was not associated with virulence genes.

H<sub>2</sub>S production and transferability of H<sub>2</sub>S producing ability were opposed with a previous study [9]. In our result, the ability of H<sub>2</sub>S production was not transferable. This phenomenon might be the different location of the genes in our isolates such as chromosome or non-transmissible plasmid which are different with a previous research [9]. Difference in H<sub>2</sub>S production was observed in TSI agar. Eight strains were not produced H<sub>2</sub>S in TSI agar. This phenomenon is coincided with a previous study showing H<sub>2</sub>S producing and lactose fermenting enteric bacteria cannot produce black colony in TSI agar due to acid production [16]. These findings suggested that bacterial H<sub>2</sub>S production can be inhibited by fermentation of lactose.

PFGE analysis of 45 strains of *E. coli* isolates indicated diversity of the isolates not showing any relatedness in H<sub>2</sub>S production. This diversity in genotypes of the isolates suggested that H<sub>2</sub>S producing strains might not belong to specific genetic clone. This relatedness was also observed in virulence genes.

As described above, H<sub>2</sub>S protects bacteria from antibiotics through inhibition of oxidative stress [24]. Thus, H<sub>2</sub>S produc-




Fig. 1. Dendrogram of PFGE patterns of *E. coli* isolates from swine feces after digestion with *Xba* I.

ing strains were expected to more resistant to antibiotics than non-producing strain. Other study showed that H<sub>2</sub>S producing strains have higher antibiotic resistance rate than non-producing strains [7]. But our result was not fully matched with previous study. Higher resistant rates were shown in 8 antibiotics (ampicillin, gentamycin, chloramphenicol, streptomycin, ciprofloxacin, enrofloxacin, sulfamethoxazole/trime-thoprim, and tetracycline) in H<sub>2</sub>S producing strains compared with non-producing strains. However, 5 antibiotics (amoxycillin/clavulanic acid, cephalothin, florfenicol, kanamycin, and nalidixic acid) were more resistant in non-producing *E. coli* isolates than H<sub>2</sub>S producing *E. coli* isolates. In statistical analysis, only cephalothin showed significant difference between H<sub>2</sub>S producing and non-producing strains. This phenomenon

might be related to presence of antibiotic resistance genes. Cellular protection effect of H<sub>2</sub>S against antibiotics can be covered due to influence of antibiotic resistance genes. Therefore, presence of antibiotic resistance genes in H<sub>2</sub>S producing *E. coli* isolates should be investigated to clarify the relationship between antibiotic resistance and H<sub>2</sub>S production. Furthermore, comparison of antibiotic susceptibility between *sseA* deficient *E. coli* and wild type *E. coli* should be needed to reveal the correlation between antibiotic resistance and H<sub>2</sub>S production.

*sseA* gene was detected in all isolates regardless of H<sub>2</sub>S production. Also, sequence of the *sseA* gene at motif CGS-GVTA around the catalytic cysteine (Cys238) was identical. These findings are contrasted with a previous research show-

ing substitution of Ser240 with lysine in *sseA* gene causing increase of H<sub>2</sub>S production with thiosulfate [3]. H<sub>2</sub>S production in *E. coli* mainly occurred through *sseA* dependent pathway, but there is an alternative pathway which regulated by other genes such as *cysN*, *cysD*, *cysC*, and *cysJIH* operon [1]. The genes *cysN*, *cysD*, and *cysC* produce enzymes such as sulfate adenylyltransferase, subunit 1, sulfate adenylyltransferase, subunit 2, and adenosine 5'-phosphosulfate kinase, respectively. *cysJIH* operon produces enzymes such as sulfite reductase beta subunit (*cysI*), sulfite reductase alpha subunit (*cysJ*), and phosphoadenosine phosphosulfate reductase (*cysH*) [1]. Mutation of gene can change activity of enzyme [3]. We assumed that production of H<sub>2</sub>S in *E. coli* might be related to mutation of *cys* genes. Therefore, sequences of the genes such as *cysN*, *cysD*, *cysC*, and *cysJIH* operon should be investigated to understand the H<sub>2</sub>S production *E. coli* in further research.

### Acknowledgments

This work was carried out with the support of "Cooperative Research Program for Agriculture Science & Technology Development (project no. PJ00897001)" Rural Development Administration, BK21 PLUS and the Research Institute for Veterinary Sciences, Seoul National University, Korea.

### References

1. **Álvarez R, Neumann G, Frávega J, Díaz F, Tejías C, Collao B, Fuentes JA, Paredes-Sabja D, Calderón IL, Gil F.** CysB-dependent upregulation of the *Salmonella* Typhimurium *cysJIH* operon in response to antimicrobial compounds that induce oxidative stress. *Biochem Biophys Res Commun* 2015, **458**, 46-51.
2. **An H, Fairbrother JM, Desautels C, Harel J.** Distribution of a novel locus called *paa* (porcine attaching and effacing associated) among enteric *Escherichia coli*. *Adv Exp Med Biol* 1999, **473**, 179-184.
3. **Colnaghi R, Cassinelli G, Drummond M, Forlani F, Pagani S.** Properties of the *Escherichia coli* rhodanese-like protein SseA: contribution of the active-site residue Ser240 to sulfur donor recognition. *FEBS Lett* 2001, **500**, 153-156.
4. **Barbour EK, Nabbut NH, Al-Nakhli HM.** Production of H<sub>2</sub>S by *Escherichia coli* isolated from poultry: an unusual character useful for epidemiology of colisepticemia. *Avian Dis* 1985, **29**, 341-346.
5. **Beaudry M, Zhu C, Fairbrother JM, Harel J.** Genotypic and phenotypic characterization of *Escherichia coli* isolates from dogs manifesting attaching and effacing lesions. *J Clin Microbiol* 1996, **34**, 144-148.
6. **Benz I, Schmidt MA.** AIDA-I, the adhesin involved in diffuse adherence of the diarrhoeagenic *Escherichia coli* strain 2787 (O126:H27), is synthesized via a precursor molecule. *Mol Microbiol* 1992, **6**, 1539-1546.
7. **Darland G, Davis BR.** Biochemical and serological characterization of hydrogen sulfide-positive variants of *Escherichia coli*. *Appl Microbiol* 1974, **27**, 54-58.
8. **Furrer B, Candrian U, Lüthy J.** Detection and identification of *E. coli* producing heat-labile enterotoxin type I by enzymatic amplification of a specific DNA fragment. *Lett Appl Microbiol* 1990, **10**, 31-34.
9. **Harnett N, Mangan L, Brown S, Krishnan C.** Thermosensitive transfer of antimicrobial resistances and citrate utilization and cotransfer of hydrogen sulfide production from an *Escherichia coli* isolate. *Diagn Microbiol Infect Dis* 1996, **24**, 173-178.
10. **Imberechts H, De Greve H, Schlicker C, Bouchet H, Pohl P, Charlier G, Bertschinger H, Wild P, Vandekerckhove J, Van Damme J, Van Montagu M, Lintermans P.** Characterization of F107 fimbriae of *Escherichia coli* 107/86, which causes edema disease in pigs, and nucleotide sequence of the F107 major fimbrial subunit gene, *fedA*. *Infect Immun* 1992, **60**, 1963-1971.
11. **Jones RT, Thai LP, Silver RP.** Genetic and molecular characterization of an *Escherichia coli* plasmid coding for hydrogen sulfide production and drug resistance. *Antimicrob Agents Chemother* 1978, **14**, 765-770.
12. **Kang HY, Jeong YS, Oh JY, Tae SH, Choi CH, Moon DC, Lee WK, Lee YC, Seol SY, Cho DT, Lee JC.** Characterization of antimicrobial resistance and class 1 integrons found in *Escherichia coli* isolates from humans and animals in Korea. *J Antimicrob Chemother* 2005, **55**, 639-644.
13. **Kimura H, Nagai Y, Umemura K, Kimura Y.** Physiological roles of hydrogen sulfide: synaptic modulation, neuroprotection, and smooth muscle relaxation. *Antioxid Redox Signal* 2005, **7**, 795-803.
14. **Kolluru GK1, Shen X, Kevil CG.** A tale of two gases: NO and H<sub>2</sub>S, foes or friends for life? *Redox Biol* 2013, **1**, 313-318.
15. **Lortie LA, Dubreuil JD, Harel J.** Characterization of *Escherichia coli* strains producing heat-stable enterotoxin b (STb) isolated from humans with diarrhea. *J Clin Microbiol* 1991, **29**, 656-659.
16. **Magalhães M, Vance M.** Hydrogen sulphide-positive strains of *Escherichia coli* from swine. *J Med Microbiol* 1978, **11**, 211-214.
17. **Maker MD, Washington JA 2nd.** Hydrogen sulfide-producing variants of *Escherichia coli*. *Appl Microbiol* 1974, **28**, 303-305.
18. **Clinical Laboratory Standards Institute.** Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests; Approved Standard—Twelfth Edition. CLSI document M02-A12. Clinical and Laboratory Standards Institute, Wayne, 2015.
19. **Ngeleka M, Pritchard J, Appleyard G, Middleton DM, Fairbrother JM.** Isolation and association of *Escherichia coli* AIDA-I/STb, rather than EAST1 pathotype, with diarrhea in piglets and antibiotic sensitivity of isolates. *J Vet Diagn Invest* 2003, **15**, 242-252.
20. **Osek J.** Prevalence of virulence factors of *Escherichia coli* strains isolated from diarrheic and healthy piglets after weaning. *Vet Microbiol* 1999, **68**, 209-217.
21. **Savarino SJ, Fasano A, Watson J, Martin BM, Levine MM, Guandalini S, Guerry P.** Enteraggagative *Escherichia coli* heat-stable enterotoxin 1 represents another subfamily of *E. coli* heat-stable toxin. *Proc Natl Acad Sci U S A* 1993, **90**, 3093-3097.

22. **Shatalin K, Shatalina E, Mironov A, Nudler E.** H<sub>2</sub>S: a universal defense against antibiotics in bacteria. *Science* 2011, **334**, 986-990.
23. **So M, McCarthy BJ.** Nucleotide sequence of bacterial transposon Tn1681 encoding a heat-stable (ST) toxin and its identification in enterotoxigenic *Escherichia coli* strains. *Proc Natl Acad Sci U S A* 1980, **77**, 4011-4015.
24. **Traub WH, Kleber I.** Characterization of two H<sub>2</sub>S-producing, multiple drug-resistant isolates of *Escherichia coli* from clinical urine specimens. *Pathol Microbiol (Basel)* 1975, **43**, 10-16.
25. **Vadivel A, Alphonse RS, Ionescu L, Machado DS, O'Reilly M, Eaton F, Haromy A, Michelakis ED, Thébaud B.** Exogenous hydrogen sulfide (H<sub>2</sub>S) protects alveolar growth in experimental O<sub>2</sub>-induced neonatal lung injury. *PLoS One* 2014, **9**, e90965.
26. **Woodward MJ, Carrol PJ, Wray C.** Detection of enterotoxin and verocytotoxin genes in *Escherichia coli* from diarrhoeal disease in animals using the polymerase chain reaction. *Vet Microbiol* 1992, **31**, 251-261.